New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:32 EDTNVIVInvivo announces BNI as third clinical trial site for neuro-spinal scaffold
InVivo Therapeutics Holdings announced that a third clinical site, the Barrow Neurological Institute, or BNI, in Phoenix, AZ, is now open for enrollment for patients with acute spinal cord injury. The first clinical site, The University of Arizona Medical Center in Tucson, AZ, was approved in April of this year under the direction of Principal Investigator Ali A. Baaj, MD, Assistant Professor of Surgery and Director, Spinal Neurosurgery Program at The University of Arizona Medical Center. A second clinical site, the Carolina Medical Center in Charlotte, NC, opened for enrollment in May of this year. Dom Coric, MD, of Carolina Neurosurgery & Spine Associates, Chief of Neurosurgery at Carolinas Medical Center, and William L. Bockenek, MD, head of Carolinas Rehabilitation, Charlotte, are Co-Principal Investigators. This is the company’s first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold. The pilot study has been approved by the FDAand is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. InVivo then expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption.
News For NVIV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
08:06 EDTNVIVInvivo says third patient improves to incomplete spinal cord injury
InVivo Therapeutics announced a one-month post-implant update for the third study patient and a six-month post-implant update for the second study patient in the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with complete acute spinal cord injury. In the time between implantation and the one-month post-injury assessment of the third study patient, the patient improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. The patient has regained sacral sensation with improved bladder function. Historically, fewer than 4% of patients with a high thoracic neurologic level of injury convert from AIS A to AIS B in the first month after injury. There were no reported serious adverse events associated with the Neuro-Spinal Scaffold. The second patient demonstrated marked improvement in sensory function with partial sensation present five dermatome levels lower on the right side compared to the three-month assessment. This translates to regaining partial sensation from the lower ribs to the hip on the right. The patient continues to make meaningful progress in activities of daily living, the company added.
June 30, 2015
08:06 EDTNVIVInVivo says Rutgers Medical School new clinical site for Neuro-Spinal Scaffold
Subscribe for More Information
June 24, 2015
07:15 EDTNVIVInternational Society for Stem Cell Research to hold annual meeting
2015 Annual Meeting of ISSCR is being held in Stockholm, Sweden on June 24-27.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use